INVIVO THERAPEUTICS HOLDINGS (NVIV) Fundamental Analysis & Valuation

NASDAQ:NVIV • US46186M6057

Current stock price

0.3207 USD
-0.17 (-34.28%)
At close:
0.231 USD
-0.09 (-27.97%)
After Hours:

This NVIV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NVIV Profitability Analysis

1.1 Basic Checks

  • In the past year NVIV has reported negative net income.
  • NVIV had a negative operating cash flow in the past year.
NVIV Yearly Net Income VS EBIT VS OCF VS FCFNVIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -97.39%, NVIV is not doing good in the industry: 82.32% of the companies in the same industry are doing better.
  • NVIV has a worse Return On Equity (-104.60%) than 71.21% of its industry peers.
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROIC N/A
ROA(3y)-47.54%
ROA(5y)-79.37%
ROE(3y)-56.17%
ROE(5y)-105.18%
ROIC(3y)N/A
ROIC(5y)N/A
NVIV Yearly ROA, ROE, ROICNVIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NVIV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVIV Yearly Profit, Operating, Gross MarginsNVIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NVIV Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for NVIV has been increased compared to 1 year ago.
  • There is no outstanding debt for NVIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NVIV Yearly Shares OutstandingNVIV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
NVIV Yearly Total Debt VS Total AssetsNVIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • NVIV has an Altman-Z score of -38.75. This is a bad value and indicates that NVIV is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -38.75, NVIV is not doing good in the industry: 92.93% of the companies in the same industry are doing better.
  • NVIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.75
ROIC/WACCN/A
WACCN/A
NVIV Yearly LT Debt VS Equity VS FCFNVIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

  • NVIV has a Current Ratio of 14.22. This indicates that NVIV is financially healthy and has no problem in meeting its short term obligations.
  • NVIV has a Current ratio of 14.22. This is amongst the best in the industry. NVIV outperforms 95.45% of its industry peers.
  • A Quick Ratio of 14.22 indicates that NVIV has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 14.22, NVIV belongs to the top of the industry, outperforming 95.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.22
Quick Ratio 14.22
NVIV Yearly Current Assets VS Current LiabilitesNVIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NVIV Growth Analysis

3.1 Past

  • NVIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.05%, which is quite impressive.
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVIV Yearly EPS VS EstimatesNVIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 -5K -10K -15K

More info and screens

Find the best growth stocksShow best growing peers

0

4. NVIV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NVIV. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVIV Price Earnings VS Forward Price EarningsNVIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVIV Per share dataNVIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVIV Dividend Analysis

5.1 Amount

  • No dividends for NVIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NVIV Fundamentals: All Metrics, Ratios and Statistics

INVIVO THERAPEUTICS HOLDINGS

NASDAQ:NVIV (2/12/2024, 8:01:31 PM)

After market: 0.231 -0.09 (-27.97%)

0.3207

-0.17 (-34.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-09
Earnings (Next)N/A
Inst Owners0.76%
Inst Owner Change-100%
Ins Owners557.87%
Ins Owner Change0%
Market Cap997.38K
Revenue(TTM)N/A
Net Income(TTM)-9.33M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.11
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.27
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -97.39%
ROE -104.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.54%
ROA(5y)-79.37%
ROE(3y)-56.17%
ROE(5y)-105.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.22
Quick Ratio 14.22
Altman-Z -38.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)182.22%
Cap/Depr(5y)128.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.64%
OCF growth 3YN/A
OCF growth 5YN/A

INVIVO THERAPEUTICS HOLDINGS / NVIV Fundamental Analysis FAQ

What is the fundamental rating for NVIV stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVIV.


What is the valuation status for NVIV stock?

ChartMill assigns a valuation rating of 0 / 10 to INVIVO THERAPEUTICS HOLDINGS (NVIV). This can be considered as Overvalued.


What is the profitability of NVIV stock?

INVIVO THERAPEUTICS HOLDINGS (NVIV) has a profitability rating of 0 / 10.


What is the financial health of INVIVO THERAPEUTICS HOLDINGS (NVIV) stock?

The financial health rating of INVIVO THERAPEUTICS HOLDINGS (NVIV) is 7 / 10.